Trial · NCT03945448
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
NCT03945448, Phase 2, Phase 3, Recruiting, Makerere University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia. Trials, record NCT03945448. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03945448
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
- NCT number
- NCT03945448
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 356 participants, estimated
- Lead sponsor
- Makerere University
- Conditions
- Cryptococcal Meningitis
- Interventions
- Single dose liposomal Amphotericin and Fluconazole, Fluconazole
- First posted
- 2019-05-10
- Last updated
- 2026-04-28
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients that develop meningitis in the AMBISOME arm compared to the fluconazole arm. | 24 weeks | Comparison will be made between those randomized to single dose liposomal amphotericin + standard of care (fluconazole) vs. standard of care (fluconazole) alone |
| Secondary | Number of grade 3 to 5 clinical adverse events or serious adverse events | within two weeks of enrollment | Symptoms causing inability to perform social and functional activities and potentially life threatening symptoms requiring intervention or hospitalization. |
| Secondary | Number of grade 3 to 5 laboratory adverse events by NIAID DAIDS toxicity scale | within two weeks of enrollment | Abnormal laboratory findings that meet the DAIDS categorization of grade 3 and 4. |
| Secondary | Cost-effectiveness of single dose liposomal amphotericin + fluconazole compared to fluconazole preemptive therapy alone, and compared to no preemptive therapy. | 24 weeks | what will be the added cost required to treat patients with AMBISOME when assessed in light of the outcomes. |
| Secondary | Number of patients that will survive in the 24-week period. | 24 weeks | How many patients will be alive at 24 weeks when the two arms are compared. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39044381 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03945448
GET https://conductscience.org/api/trials/v1/NCT03945448/registered